- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
The US Food and Drug Administration (FDA) announced today Pfizer/BioNTech has requested emergency use authorisation (EUA) for its vaccine in children as young as six months. According to the announcement, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on 15 February to review the data. The formulation being proposed would be for children aged six months, up to four years. The Pfizer/BioNTech vaccine is already approved in the US for those aged 5 and over. The VRBPAC meeting will be webcast on the FDA website, as well as on the agency’s YouTube channel.
Further information on the Pfizer/BioNTech vaccine may be found here.
Pandemic Information Webinars
(Available to Pandemic Subscribers only)
Register for upcoming events
View/Download previous webinars
Additional data provided by
English
Japanese
